(UroToday.com) On the first day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022, Poster Session A focussed on the care of patients with prostate cancer. Dr. Miura presented a poster outline a multi-institutional validation of the STAR-CAP clinical prognostic system for predicting biochemical recurrence after radical prostatectomy. STAR-CAP is an international staging collaboration for cancer of the prostate that was recently established and used for predicting oncological outcomes for patients with prostate cancer. In this work, the authors undertook independent validation of the STAR-CAP prognostic model for Japanese patients with prostate cancer and compared it to the CAPRA score for the prediction of biochemical recurrence (BCR) after radical prostatectomy.
To do so, the authors retrospectively analyzed data from a multi-institution database of 1,645 patients who underwent radical prostatectomy between 2010 and 2020. Patients were excluded if they had inadequate follow-up duration ( < 1 year), missing or incomplete perioperative clinical parameters relevant for STAR-CAP, or received neoadjuvant therapy. BCR was defined as two consecutive prostate-specific antigen values ≥ 0.2 ng/mL. The 3-year BCR-free survival was assessed by Kaplan-Meier analyses and log-rank test. The performance of both models to predict 3-year BCR-free survival was assessed using the area under the curve (AUC).
The authors found that 3-year BCR-free survival ranged from 47.3% (high risk) to 93.5% (low risk) in the STAR-CAP classification (p< 0.001) and from 62.5% (high risk) to 94.6% (low risk) in the CAPRA classification (p< 0.001).
AUCs for the 3-year BCR prediction were 0.756 and 0.784 for STAR-CAP and CAPRA, respectively, demonstrating essentially comparable predictive ability.
Thus, the authors conclude that, among Japanese patients undergoing radical prostatectomy, both STAR-CAP and CAPRA prognostic systems provide sufficient stratification and have comparable predictive ability for 3-year BCR-free survival.
Presented by: Noriyoshi Miura PhD, MD, Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan